894 results about "Blood drug concentration" patented technology

The present invention discloses a slowly-released oral medicine preparation which is made up by using breviscapine as main raw material and has the functions of promoting blood circulation and removing blood stasis, removing obstruction in the channels to relieve pain for curing angiocardiopathy and cerebrovascular disease with obvious therapeutic effect and its preparation method. Said slowly-released tablet (by one tablet) contains 60-120 mg of breviscapine, 20-75 mg of diluent, 50-150 mg of filling agent and 10-50 mg of slow release material. Said invention also provides its preparation method and concrete steps.

The invention discloses a colchicine bilayer sustained-release tablet which comprises a quick release layer and a sustained-release layer, wherein the quick release layer mainly consists of colchicine, a disintegrant, a filler, a lubricant and an adhesive; the sustained-release tablet mainly consists of colchicine, a sustained-release matrix, a retarding agent, a filler and an adhesive; the weight ratio of the colchicine in the quick release layer to the colchicine in the sustained-release layer is (0.25-0.42) : 1; and the weight ratio of the quick release layer to the sustained-release layer is 1: 2 to 1: 4. The invention also discloses a method for preparing the colchicine bilayer sustained-release tablet. The colchicine bilayer sustained-release tablet releases the drugs through the quick release layer to quickly achieve the effective blood drug concentration, slowly releases the drugs through the sustained-release layer to exert and sustain the stable and uniform effective blood drug concentration, reduces the drug taking times and lightens the toxic or side function.

The invention provides a nimodipine lipid microsphere injection, which is prepared from the following components in percentage by weight: 0.08 percent of nimodipine, 0.5 to 2.3 percent of lecithin for injection, 2 to 8 percent of soybean oil for injection, 2 to 8 percent of medium chain fatty acid for injection, 1 to 3 percent of glycerin, 0.1 to 0.2 percent of tween-80, 0.03 to 0.05 percent of sodium oleic acid, and the balance being water for injection. The preparation method comprises steps of preparation of an oil phase, preparation of water phase, preparation of colostrum, homogenization and canning. In the nimodipine lipid microsphere injection, the soybean oil for injection and the medium chain fatty acid for injection are used to prepare the oil phase, the nimodipine is a fat soluble drug and can be better dissolved in the oil phase, the lipid microsphere in which the soybean oil for injection is the main component has solvent characteristics, is non-toxic, and can guide the fat soluble drugs to be dissolved in emulsion particles and perform the metabolism along with lipid oil drops and slowly release, thereby maintaining the effective blood concentration, lowering toxic and side effects of the drugs, increasing the solubility and stability of the nimodipine drug, improving the drug-loading rate and reducing the hydrolysis of the drugs.

The invention discloses guanidine hydrochloride sustained release preparation and a preparation method thereof. The guanidine hydrochloride sustained release preparation is mainly prepared by guanidine hydrochloride, a filling agent, sustained release materials and potential of hydrogen (pH) sensitive materials. The preparation method comprises the steps of firstly preparing all raw materials according to proportion, evenly mixing the guanidine hydrochloride, the filling agent, the sustained release materials and the pH sensitive materials at high speed, granulating and drying the evenly mixed powder, finally adding a flow agent, a lubrication agent and an adhesion agent, tableting according to a general method, and achieving guanidine hydrochloride sustained release tablets. The guanidine hydrochloride sustained release preparation is small in side effect, obviously reduces difference of preparation of different batches, improves stability of samples, is convenient long term curing of patients and improves compliance of medicine. A patient can take the guanidine hydrochloride sustained release tablets once a day, so that effective drug concentration in bodies can be guaranteed for 24 hours, and nervous centralis side reactions caused by the fact that a blood concentration peak value is high due to general preparation is reduced.

The invention discloses a sinomenine or an enteric-coated controlled-release tablet of hydrochloride thereof. The prepared enteric-coated controlled-release tablet hardly releases the drug in artificial simulated gastric juice, but can slowly and smoothly release the drug in artificial simulated intestinal juice; the sustained release time of the drug can achieve more than 12 hours or even 24 hours; the enteric-coated controlled-release tablet is taken once or twice daily, the plasma drug concentration in vivo is smooth, and the peak-valley phenomenon of the plasma drug concentration is reduced; as the prepared enteric-coated controlled-release tablet hardly releases the drug in stomach, the contacted concentration of the drug with the gastric mucosa is small, the stimulation of the stomach caused by the drug is alleviated. As the prepared enteric-coated controlled-release tablet sustainedly slowly releases the drug in intestinal tract, the times of the drug administration are reduced, and the patient compliance is improved, thereby being applicable to the needs of the clinical development.

A controlled release dosage form of tacrolimus, comprising a solid dispersion of tacrolimus, wherein a controlled release base, which is selected from the group consisting of a water-soluble macromolecule, a gum base, and a membrane forming agent and does not form the solid dispersion of tacrolimus, is further contained, is disclosed. The controlled release dosage form of tacrolimus has an excellent controlled release and shows a stable blood concentration.

The invention discloses an immunomodulator slow-release preparation and a preparation method thereof. A lenalidomide slow-release tablet is composed of a slow-release layer and an optional quick-release layer, wherein the slow-release layer contains active ingredients of lenalidomide and a slow-release framework material simultaneously; the quick-release layer does not contain the slow-release framework material. The lenalidomide slow-release tablet disclosed by the invention is capable of slowly and uniformly releasing medicines by virtue of the slow-release framework material, so as to reduce the release speed, delay the time to peak, prolong the action time of lenalidomide, and provide a uniform and constant blood concentration. Moreover, The lenalidomide slow-release tablet disclosed by the invention is simple in prescription and excellent in quality stability; the preparation process is simple to operate, free from special treatment and production equipment, low in production cost, and beneficial to batch-enlarged industrial production for the product; the preparation method is high in yield, the granulation and crushing procedures are simple and practicable to operate, the intermediate material is good in stability, flowability, compressibility and content uniformity, and completely meets the requirements of tabletting, and the surface of the prepared tablet is smooth and beautiful.

The invention relates to oral double iguratimod controlled release formulation, which comprises fast release layer and slow release layer that are composed of 8-30% micronizing iguratimod crystal powder and medical findings, and the granule size of iguratimod crystal powder is 1-10 um. The effective component in fast release layer is released in short time and reaches to effective blood chemical concentration for effective action; the iguratimod in sloe release layer is released gradually and maintains effective blood medical concentration for continuous effective action. The invention overcomes shortcomings of short effective action time and a little high toxic effect.

The present invention discloses an accurate quantitative analysis method for an ion mobility spectrum rapid detection sample. According to the method, based on the migration time obtained through qualitative analysis of an ion mobility spectrum, the thermal analysis process of the whole sample to be detected is completely recorded, and the recorded curve is defined as the tracking trend line of the thermal analysis of the sample; the samples with different concentrations are prepared by adopting the ion mobility spectrum technology as the base detection technology, and the tracking trend of the sample is subjected to data analysis; and by adopting the propofol in blood as an example, a standard curve equation y=671.48+934.42.x of the ion mobility spectrum detection is established between the plasma concentration of 1-20 ppm, wherein the correlation coefficient r is 0.9928. According to the present invention, the method is simple, rapid and efficient, and can be widely used for the quantitative analysis of the ion mobility spectrum rapid detection sample.

The invention discloses a method for measuring blood concentration of paraquat. The method comprises the following steps of: (1) pretreating a sample, namely adding aqueous solution of an internal standard substance and a protein precipitation agent acetonitrile into a plasma sample, performing whirl mixing, centrifuging and sampling supernatant; (2) separating the sample, namely adopting a universal C18 liquid chromatographic column, and using an ion pairing agent in an acid mobile phase, wherein the acid mobile phase is mixed solution of 3mmol.L<-1> aqueous solution of sodium dodecyl sulfate, 0.2 percent of aqueous solution of trifluoroacetic acid, acetonitrile and water; and (3) detecting by using a diode array detector, namely detecting by using the diode array detector at a detectionwavelength of 250 to 260nm, measuring peak areas of the internal standard substance and the paraquat, and calculating the blood concentration of the paraquat through least square method linear regression. The plasma sample is easy and convenient to pretreat, the detection process is sensitive and rapid, toxic substances and the blood concentration thereof can be rapidly determined in actual application, and the method is high in clinical application value.

The invention discloses an isosorbide mononitrate timing controlled release preparation and a preparation method thereof. The isosorbide mononitrate timing controlled release preparation of the present invention has certain time-lag and long-acting stationary release, and comprises a semi-permeable membrane with drug release apertures, an isolating coating and a double layer label including a drug contained layer and a boosting layer. The isosorbide mononitrate timing controlled release preparation of the present invention is an osmotic pump tablet with certain time-lag and long-acting stationary release, and can provide a more lasting and stationary plasma concentration and is bioequivalent compared with a sale long-acting preparation Elantan.

The invention discloses a new formulation of a new non-steroidal anti-inflammatory drug zaltoprofen-a sustained-release preparation of the zaltoprofen and a preparation method thereof; each tablet/each granule of the zaltoprofen sustained-release preparation contains 80 to 240mg of the zaltoprofen and 10 to 120mg of excipients which play the sustained-release function; the sustained-release preparation is conductive to the long-term maintenance of the effective plasma-drug concentration and can improve the efficacy, reduce the side effects, reduce the times of being taken and facilitate the taking and the carry.

The invention relates to a sustained release tablet dosage, in particular to a Tacrolimus sustained release tablet used for liver and kidney transplantation patients and a preparation method thereof, belonging to the field of medicine technology. The invention is characterized in that Tacrolimus and adhesive are taken and dissolved in ethanol to prepare Tacrolimus solution; sustained release materials, thinner and flow agent are taken, mixed and dispersed uniformly and then added into the Tacrolimus solution to prepare wet particles, which are dried, ground and added and mixed with lubricant; finally, the Tacrolimus sustained release tablet is prepared after tabletting and drying. The sustained release tablet has the unique advantages of: reducing administration times, improving the administration adaptability of patients; after administration, having stable blood concentration, small toxic and side effects and improving the drug effect and safety; reducing the total dosage of drugs so as to achieve the greatest curative effect by the lowest dosage; being capable of being realized on most of tablet production lines and easily accepted by manufacturing units and manufacturers due to relatively simple preparation process; and having relatively low manufacturing cost and broad clinical application prospect.

The invention relates to a dasatinib liposome preparation, and a preparation method thereof. The dasatinib liposome preparation is high in biocompatibility; target modification can be carried out; sustained and controlled release of dasatinib can be realized; and it is beneficial for maintenance of relatively high plasma drug concentration in a long term, improvement of drug distribution, and increasing of drug bioavailability. The dasatinib liposome preparation possesses excellent lipophilic performance, is capable of passing through phospholipid bilayer in a molecular form and entering into inner water phase; pH value of liposome inner water phase is relatively low, the dasatinib moleculars are capable of bonding with hydrogen ions so as to form dasatinib ions, and combination with anions in an ammonium salt solution and forming of insoluble salts are realized, diffusion of dasatinib in the inner water phase into an outer water phase is inhibited, dasatinib is coated by the liposome inner water phase steadily, encapsulation efficiency and storage stability are improved, and excellent in-vitro slow release effect is achieved.

The invention relates to the field of biological medicines, and in particular to a composition of beta-nicotinamide mononucleotide or a beta-nicotinamide mononucleotide precursor, and a preparation method and application of the composition. The composition comprises the following raw materials in percentage by weight: 0.001 to 25 percent of beta-nicotinamide mononucleotide or a precursor thereof,0 to 20 percent of a transdermal absorption enhancer, 2 to 50 percent of an auxiliary component and the balance of water. After being absorbed by a human body in a mode of transdermal administration or external administration, the composition can exert effects of improving internal functions of a human body, improving metabolism of a human body or improving epidermal functions of a human body, andresisting skin inflammation, allergy and skin aging. Through the mode of transdermal administration and external administration, metabolic burden of liver and kidney can be avoided, blood concentration can be kept constant, and administration is convenient.

The invention relates to liposome of extract of cordyceps and a method for preparing the same. The main composition of the extract is polysaccharide. The liposome of the cordyceps is prepared by using phospholipid and cholesterol as membrane materials, and the prepared liposome of the cordyceps can be further prepared into dosage forms of tablet, injection, oral agent, capsule, granule, freeze-dried powder and the like. The method for preparing the liposome of the cordyceps can adopt a reverse evaporation method, a film ultrasound method and an ethanol injection method, the encapsulation rate of the methods can reach more than 40 percent, and the in vitro burst rate is low. The preparing process improves the stability of the drug. After the polysaccharide of the cordyceps is coated with the liposome, the polysaccharide of the cordyceps can be absorbed and used better in human body; and through the slow release effect of the liposome, the effective blood drug level of the drug can be maintained for a longer time.

The invention discloses an esomeprazole-containing medicinal composition, which contains esomeprazole and a buffering agent. The problem that an esomeprazole magnesium enteric preparation is slowly absorbed is solved through the medicinal composition; and the medicinal composition is convenient to takeeat, is takeneaten for only one time everyday when a patient is in an empty belly state (at least 1 hour before meal), and can quickly reach the maximal blood concentration (within about 30 minutes) and control gastric acid very effectively.

The invention relates to an isosorbide mononitrate sustained-release tablet and a preparation method thereof, belonging to the technical field of medicinal preparations. The sustained-release tablet comprises a coating of isosorbide mononitrate drug loaded microballoons which account for 48% to 55% of the total weight of the tablet and a quick-release layer which accounts for 45% to 52% and comprises isosorbide mononitrate, a binder, a filler and a lubricant. According to the invention, isosorbide mononitrate is divided into two parts, i.e., the part of quick release and the part of sustained release, which enables the tablet to take effect rapidly at an initial stage of administration, maintain an effective plasma concentration after the effective plasma concentration is reached and retain the effective plasma concentration at a low level so as to reduce residual quantity of the tablet at administration time of the tablet the next day, thereby effectively avoiding generation of drug resistance.